Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 31, 2020, titled "Press Release Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA�� (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis".